Shopping Cart 0
Cart Subtotal
AED 0

Anal Cancer - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 22020

Details

Anal Cancer-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer-Pipeline Review, H1 2019, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 16, 10 and 5 respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Introduction

Anal Cancer-Overview

Anal Cancer-Therapeutics Development

Anal Cancer-Therapeutics Assessment

Anal Cancer-Companies Involved in Therapeutics Development

Anal Cancer-Drug Profiles

Anal Cancer-Dormant Projects

Anal Cancer-Discontinued Products

Anal Cancer-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Anal Cancer, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Anal Cancer, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Anal Cancer-Pipeline by Antiva Biosciences Inc, H1 2019

Anal Cancer-Pipeline by Bayer AG, H1 2019

Anal Cancer-Pipeline by BeiGene Ltd, H1 2019

Anal Cancer-Pipeline by Bristol-Myers Squibb Co, H1 2019

Anal Cancer-Pipeline by Cleveland BioLabs Inc, H1 2019

Anal Cancer-Pipeline by Cue Biopharma Inc, H1 2019

Anal Cancer-Pipeline by CytomX Therapeutics Inc, H1 2019

Anal Cancer-Pipeline by Eli Lilly and Co, H1 2019

Anal Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Anal Cancer-Pipeline by Fujifilm Holdings Corp, H1 2019

Anal Cancer-Pipeline by Genentech Inc, H1 2019

Anal Cancer-Pipeline by IMV Inc, H1 2019

Anal Cancer-Pipeline by Incyte Corp, H1 2019

Anal Cancer-Pipeline by ISA Pharmaceuticals BV, H1 2019

Anal Cancer-Pipeline by Kite Pharma Inc, H1 2019

Anal Cancer-Pipeline by MedImmune LLC, H1 2019

Anal Cancer-Pipeline by Merck & Co Inc, H1 2019

Anal Cancer-Pipeline by Merck KGaA, H1 2019

Anal Cancer-Pipeline by OncoMed Pharmaceuticals Inc, H1 2019

Anal Cancer-Pipeline by Onconova Therapeutics Inc, H1 2019

Anal Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H1 2019

Anal Cancer-Pipeline by PDS Biotechnology Corp, H1 2019

Anal Cancer-Pipeline by Sierra Oncology Inc, H1 2019

Anal Cancer-Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2019

Anal Cancer-Pipeline by Transgene SA, H1 2019

Anal Cancer-Pipeline by Virion Therapeutics LLC, H1 2019

Anal Cancer-Dormant Projects, H1 2019

Anal Cancer-Discontinued Products, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Antiva Biosciences Inc

Bayer AG

BeiGene Ltd

Bristol-Myers Squibb Co

Cleveland BioLabs Inc

Cue Biopharma Inc

CytomX Therapeutics Inc

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Fujifilm Holdings Corp

Genentech Inc

IMV Inc

Incyte Corp

ISA Pharmaceuticals BV

Kite Pharma Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

OncoMed Pharmaceuticals Inc

Onconova Therapeutics Inc

Ono Pharmaceutical Co Ltd

PDS Biotechnology Corp

Sierra Oncology Inc

THEVAX Genetics Vaccine USA Inc

Transgene SA

Virion Therapeutics LLC

Company Profile

Company Profile Title

Anal Cancer-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer-Pipeline Review, H1 2019, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 16, 10 and 5 respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Introduction

Anal Cancer-Overview

Anal Cancer-Therapeutics Development

Anal Cancer-Therapeutics Assessment

Anal Cancer-Companies Involved in Therapeutics Development

Anal Cancer-Drug Profiles

Anal Cancer-Dormant Projects

Anal Cancer-Discontinued Products

Anal Cancer-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Anal Cancer, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Anal Cancer, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Anal Cancer-Pipeline by Antiva Biosciences Inc, H1 2019

Anal Cancer-Pipeline by Bayer AG, H1 2019

Anal Cancer-Pipeline by BeiGene Ltd, H1 2019

Anal Cancer-Pipeline by Bristol-Myers Squibb Co, H1 2019

Anal Cancer-Pipeline by Cleveland BioLabs Inc, H1 2019

Anal Cancer-Pipeline by Cue Biopharma Inc, H1 2019

Anal Cancer-Pipeline by CytomX Therapeutics Inc, H1 2019

Anal Cancer-Pipeline by Eli Lilly and Co, H1 2019

Anal Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Anal Cancer-Pipeline by Fujifilm Holdings Corp, H1 2019

Anal Cancer-Pipeline by Genentech Inc, H1 2019

Anal Cancer-Pipeline by IMV Inc, H1 2019

Anal Cancer-Pipeline by Incyte Corp, H1 2019

Anal Cancer-Pipeline by ISA Pharmaceuticals BV, H1 2019

Anal Cancer-Pipeline by Kite Pharma Inc, H1 2019

Anal Cancer-Pipeline by MedImmune LLC, H1 2019

Anal Cancer-Pipeline by Merck & Co Inc, H1 2019

Anal Cancer-Pipeline by Merck KGaA, H1 2019

Anal Cancer-Pipeline by OncoMed Pharmaceuticals Inc, H1 2019

Anal Cancer-Pipeline by Onconova Therapeutics Inc, H1 2019

Anal Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H1 2019

Anal Cancer-Pipeline by PDS Biotechnology Corp, H1 2019

Anal Cancer-Pipeline by Sierra Oncology Inc, H1 2019

Anal Cancer-Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2019

Anal Cancer-Pipeline by Transgene SA, H1 2019

Anal Cancer-Pipeline by Virion Therapeutics LLC, H1 2019

Anal Cancer-Dormant Projects, H1 2019

Anal Cancer-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Antiva Biosciences Inc

Bayer AG

BeiGene Ltd

Bristol-Myers Squibb Co

Cleveland BioLabs Inc

Cue Biopharma Inc

CytomX Therapeutics Inc

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Fujifilm Holdings Corp

Genentech Inc

IMV Inc

Incyte Corp

ISA Pharmaceuticals BV

Kite Pharma Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

OncoMed Pharmaceuticals Inc

Onconova Therapeutics Inc

Ono Pharmaceutical Co Ltd

PDS Biotechnology Corp

Sierra Oncology Inc

THEVAX Genetics Vaccine USA Inc

Transgene SA

Virion Therapeutics LLC